NCT07459634: An ongoing trial by Jazz Pharmaceuticals
This trial is ongoing. It must report results 2 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07459634 |
|---|---|
| Title | A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 12, 2026 |
| Completion date | Jan. 31, 2028 |
| Required reporting date | Jan. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 24, 2026 |
| Days late | None |